Contrast-Enhanced Mammography (CEM) for Detecting Residual Disease after Neoadjuvant Chemotherapy: A Comparison with Breast Magnetic Resonance Imaging (MRI)

<div>39-year-old woman. Invasive ductal carcinoma with pathologic complete response. Pre- and post-NAC FFDM (a), CEM (b), and MRI (c). Focal asymmetry is seen in the outer quadrant in FFDM (a). Pre-NAC CEM (b) and MRI (c) show segmental non-mass enhancement. Post-NAC FFDM (a) and MRI (c) incorrectly showed residual disease (arrow) while CEM was truly negative.</div>

BioMed Research International

fig4

Figure 4

Figure 4: Contrast-Enhanced Mammography (CEM) for Detecting Residual Disease after Neoadjuvant Chemotherapy: A Comparison with Breast Magnetic Resonance Imaging (MRI) 

Figure 4 | Contrast-Enhanced Mammography (CEM) for Detecting Residual Disease after Neoadjuvant Chemotherapy: A Comparison with Breast Magnetic Resonance Imaging (MRI) 